HUA MEDICINE-B News

HUA MEDICINE-B: Annual Report 2024

HKEXApr 24 05:32 ET · Announcements

What Hua Medicine (Shanghai) Ltd.'s (HKG:2552) 30% Share Price Gain Is Not Telling You

Simply Wall StMar 30 21:30 ET

Hua Ling Medicine (02552): The benefits of medical insurance are gradually being realized, commercialization is exploding, and Global expansion is opening a new chapter.

On March 27, Hualing Pharmaceutical (02552) delivered a remarkable performance report for 2024 that caught the market's attention.

Zhitong FinanceMar 28 04:26 ET

Hong Kong stocks moving | HUA MEDICINE-B (02552) rose over 4% after earnings, with annual gross profit increasing over 2.3 times year-on-year, expecting a significant rise in sales after Huatang Ning's entry into the insurance.

HUA MEDICINE-B (02552) rose over 4% after the earnings report, as of the time of writing, it has increased by 4.65%, priced at 2.7 Hong Kong dollars, with a trading volume of 6.5766 million Hong Kong dollars.

Zhitong FinanceMar 27 21:41 ET

HUA MEDICINE-B (02552) announced its annual performance with a gross profit of 0.125 billion yuan, an increase of 233.72% year-on-year.

HUA MEDICINE-B (02552) announced its annual performance for the year ending December 31, 2024, with revenue of 2....

Zhitong FinanceMar 27 04:55 ET

Express News | Hua Medicine FY Pretax Profit RMB -250.1 Million

ReutersMar 27 04:42 ET

Express News | Hua Medicine FY Revenue RMB 255.9 Million

ReutersMar 27 04:42 ET

HUA MEDICINE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024

HKEXMar 27 04:42 ET · Announcements

HUA MEDICINE-B (02552.HK) will hold a Board of Directors meeting on March 27 to consider and approve the annual performance.

Gelonghui reported on March 17 that HUA MEDICINE-B (02552.HK) announced that the Board of Directors meeting is scheduled for March 27, 2025 (Thursday) to consider and approve the annual full-year results of the group for the year ended December 31, 2024, the proposed final dividend (if any), and to address Other matters.

Gelonghui FinanceMar 17 04:31 ET

HUA MEDICINE-B: Date of Board Meeting

HKEXMar 17 04:30 ET · Announcements

The bull market for Hong Kong stocks has begun; how to identify the certainty of value growth?

At present, the technical bull market in the Hong Kong stock market is becoming the focus of attention for global investors.

Gelonghui FinanceMar 3 19:44 ET

Hong Kong stocks movement | HUA MEDICINE-B (02552) rose nearly 30% in the afternoon. The company has built its own sales team to advance the commercialization process of Huadongning.

HUA MEDICINE-B (02552) rose nearly 30% in the afternoon, as of the time of writing, it rose by 24.12%, trading at 2.11 Hong Kong dollars, with a transaction volume of 20.8871 million Hong Kong dollars.

Zhitong FinanceFeb 19 00:55 ET

The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?

Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.

wallstreetcnFeb 7 20:59 ET

HUA MEDICINE-B (02552): HUA MEDICINE Shanghai formally delivered a termination notice to Bayer according to the agreement.

HUA MEDICINE-B (02552) announced that on December 31, 2024, HUA MEDICINE in Shanghai will, according to the agreement, supply to Ba...

Zhitong FinanceDec 31, 2024 05:08 ET

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24, 2024 04:16 ET

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8, 2024 23:10 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8, 2024 03:48 ET

Hualing Pharmaceutical announced the successful completion of Phase I clinical trials for its second-generation glucokinase activator conducted in the usa.

Shanghai, November 30, 2024 /PRNewswire/ -- Hualing Pharmaceutical ("the company", Hong Kong Stock Exchange stock code: 2552.HK) today announced at the 9th China BioMed Innovation and Investment Conference (CBIIC) that it has successfully completed the Phase Ia clinical study of the second-generation glucose kinase activator (GKA) conducted in the USA. The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) is

PR NewswireNov 30, 2024 04:23 ET

Hua Ling Pharmaceuticals announces the successful completion of the SENSITIZE study conducted in hong kong, china.

On November 30, 2024, shanghai /美通社/ -- china meheco group ("company", Stock code: 2552.HK on the Hong Kong Stock Exchange) announced today at the 9th China BioMed Innovation and Investment Conference (CBIIC) that the company has successfully completed the SENSITIZE research in collaboration with Professor Juliana Chan's team at the Chinese University of Hong Kong, aiming to improve β cell function using DPP-4 Inhibitors.

PR NewswireNov 30, 2024 04:23 ET

Hualead Pharmaceuticals-B (02552): Termination of Bayer Hofmann's agency sales rights from January 1, 2025.

Hua Ling Medicine-B (02552) announced that the company has sent a written notice to Bayer Healthcare LLC, indicating its intention to transfer the commercialization responsibility of the innovative glucose kinase activator, Huatangning, developed for the treatment of type 2 diabetes in china, to the company starting from January 1, 2025.

Zhitong FinanceNov 21, 2024 21:05 ET